Disruptive Approaches To Accelerate Drug Discovery and Development (Part 1) By Ibis Sanchez- Serrano, Dr Tom Pfeifer and Dr Rathnam Chaguturu This article is part 1 of 2, and covers tools, technologies and the core model of disruptive approaches to accelerate drug discovery and development. Tesla intends to implement and… Read More
The Use of Next-Generation Sequencing in Drug Development By Keith Nangle & Mike Furness This article summarises some of the technical and regulatory challenges posed by next-generation sequencing technologies and the efforts being made to address them. Next-generation sequencing (NGS) has moved from the realm of research into those of… Read More
Therapeutic Antibodies - New tools to enhance the antibody drug pipeline By Dr Robert Ford & Dr Toni Hoffmann Therapeutic antibodies are the fastest growing class of drugs, with continuous increases in the number of innovator and biosimilar drugs in development. Drug development and clinical trials necessitate the ability to… Read More
By Dr Jason Mellad The sequencing of the human genome in 2003 signalled the dawn of an exciting new era for genetic medicine. Yet almost 15 years later it has become clear that our genes alone cannot predict our susceptibility to most complex diseases or fully explain fundamental aspects of… Read More
Drug Discovery in the Age of Big Data - The Impact of RNAi & CRISPR/Cas9 Technologies By Dr Prem Premsrirut This article discusses how RNA interference and CRISPR/Cas9 technologies are helping to build better mouse models and push drug discovery into a new era. Most, if not all, consumers are… Read More
Nanoparticles & Nanomedicines - Exploring The Past, Present and Future By Professor Yvonne Perrie & Dr Euan Ramsay Nanoparticles, and liposomes in particular, are growing in popularity as drug delivery vehicles for anti-cancer agents and inflammatory disease therapies, as well as forming the basis of a new class of vaccines. Read More
New Approaches to Sample Identification Tracking and Technologies for Maintaining Stored Sample Quality By Dr John Comley Safeguarding the quality of stored samples (both compounds and biospecimens) must be the driving ethos in compound management stores and biorepositories. Yet there are few innovations in available sample storage technologies that can… Read More
Raising The Bar On The Biologics Potential Dr Michael Mouradian In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a significant time commitment. Read More
Monitoring the Balance Between Immune Repression and Stimulation in Cancer Immunotherapy By Dr Peter Schulz-Knappe and Dr Georg Lautscham Cancer is still one of the main causes of death worldwide, yet recent strides towards more effective treatments have been made in the form of new cancer immunotherapies. By weaponising the… Read More
A Marriage of Technologies for Immuno-Oncology In Vivo Studies By Dr Philip Dube Discovering and validating novel therapeutic targets to add to the immuno-oncology arsenal will require refined preclinical models that meet the needs for suitability, scalability and clinical relevancy throughout the various phases of target discovery and drug validation. Read More
Kinases and Drug Discovery: Protein Kinases as a Validated Drug Target By Professor Said A. Goueli The role of protein and lipid kinases in cellular physiology and normal and abnormal growth has been well appreciated and has been the focus of intensive research in both academic arenas and pharmaceutical industries. Read More
Automated Liquid Handler Vendor vs Third Party Plastic Company by Dr John Comley Competing for the disposable pipette tip business. Users of automated liquid handlers today invariably have a choice – obtain disposable pipette tips from the original instrument vendor or purchase a 'compatible' product from a third party plastics… Read More
Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine By Dr Mukund Chorghade, Dr Michael Liebman, Dr Gerald Lushington, Dr Stephen Naylor and Dr Rathnam Chaguturu As yesterday’s lead molecule enters today’s clinical trial, the standard operating script seems to call for product developers and clinicians… Read More
Why Adopting AI is Essential for a Sustainable Pharma Industry By Professor Jackie Hunter Advancements in technology, and in particular, developments in artificial intelligence (AI) are revolutionising the way that we live our lives. Up to now, we have used it to help us find the quickest route home or… Read More
I Robot. I, The Future - Robotics Within and Beyond The Lab Richard Holland The Pistoia Alliance (whose membership includes most of the world’s major pharmaceutical companies, technology vendors and publishers active in the life science R&D sector), is keenly interested in discovering the ways in which innovation through pre-competitive… Read More
CRISPR Cas9: Transforming Gene Editing in Drug Discovery Labs By Dr John Comley It is evident from a recent market survey on gene editing in drug discovery that CRISPR/Cas9 is now recognised as the superlative method when attempting a gene knockout or when introducing defined mutations, insertions or modifications to… Read More